Systemic immune reactions to HMG-CoA reductase inhibitors: Report of 4 cases and review of the literature

Medicine

Volumn 77, Issue 6, 1998, Pages 378-383

  Rudski, Lawrence ^a   Rabinovitch, Mark A ^a,b   Danoff, Deborah ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOPATHOLOGY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 0031671966     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199811000-00002     Document Type: Article

References (25)

1. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 151: 1667-68, 1991.
2. Ballare M, Campanini M, Airoldi G, Zaccala G, Bertoncelli MC, Cornaglia G, Porzio M, Monteverde A. Hepatotoxicity of HMG Co-A reductase inhibitors. Minerva Gastroenterol Dietol 38: 41-44, 1992.
3. Bannwarth B, Miremont G, Papapietro P-M. Lupuslike syndrome associated with simvastatin. Arch Intern Med 152: 1093, 1992.
4. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Arch Intern Med 151: 43-49, 1991.
5. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, Rackley CE. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 131: 663-67, 1996.
6. Careless DJ, Cohen MG. Rheumatic manifestations of hyperlipidemia and antihyperlipidemia drug therapy. Semin Arthritis Rheum 23: 90-98. 1993.
7. Coblyn JS, Weinblatt ME. Rheumatic diseases and the heart. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. 5th ed. Philadelphia: WB Saunders, p 1778, 1997.
8. Fosso C, Miller M, Solomon W, Baker J. Adverse effects of HMG Co-A reductase inhibitors associated with elevated serum IgE and eosinophilia. J Allergy Clin Immunol 95: 1053-55, 1995.
9. Fritzler MJ, Rubin RL. Drug-induced lupus erythematosus. In: Wallace DJ, Rubin RL. Drug-induced lupus erythematosus. 3rd ed. Philadelphia: Lea & Febiger, p 442, 1987.
10. Gillis MC, ed. Compendium of pharmaceuticals and specialties. 32nd ed. Ottawa, Ontario, Canada: Canadian Pharmaceutical Association, p 1803, 1997.
11. Hess EV, Mongey A. Drug-related lupus: The same as or different from idiopathic disease? In: Lahita RG, ed. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone, p 893, 1992.
12. Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Kelly WN, Harris ED Jr, Ruddy S, Sludge CB, eds. Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders, p 1123, 1997.
13. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 33: 199, 1994.
14. Mantell G, Burke MT, Staggers J. Extended clinical safety profile of lovastatin. Am J Cardiol 66: 11B-15B, 1990.
15. McCormack JP, Rangno RE. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. Can J Clin Pharmacol 1: 27-32, 1994.
16. Pederson TR, Berg K, Cook TJ, Foergeman O, Haghfelt T, Kjekshus J, Miettenen T, Musliner RA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156: 2085-92, 1996.
17. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 71-291-302, 1992.
18. Puurunen M, Manttari M, Manninen V, Tenkanen L, Afthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154: 2605-9, 1994.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-9, 1996.
20. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-89, 1994.
21. Schalke BB, Schmidt B, Toyka K, Hartung H-P. Pravastatin- associated inflammatory myopathy. N Engl J Med 327: 649-50, 1992.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AH, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-7, 1995.
23. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 28J-43J, 1988.
24. Vaarala O, Alfthan G, Jauhianen M, Leirisalo-Repo, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923-25, 1993.
25. Vial T, Nicolas B, Descotes J. Drug-induced autoimmunity: Experience of the French Pharmacovigilance system. Toxicology 119: 23-27, 1997.